a Department of Expanded Programme on Immunization , Jiangsu Provincial Center for Disease Control and Prevention , Nanjing , China.
b Department of Health education , Jiangsu Provincial Center for Disease Control and Prevention , Nanjing , China.
Expert Rev Vaccines. 2018 May;17(5):445-452. doi: 10.1080/14760584.2018.1445529. Epub 2018 Mar 12.
In China, one dose measles-mumps-rubella vaccine (MMR) was administered to children aged 18-24 months. The mumps incidence was still high. Data on the waning immunity to mumps after MMR vaccination are limited. This study aimed to describe the waning immunity to mumps in kindergarten and primary school children to provide a scientific basis for confirming an optimal age for a second dose.
An observational, prospective study on one-dose MMR in children in kindergarten and primary school was conducted from 2015 to 2016. Waning immunity to mumps in terms of seropositivity and geometric antibody concentration (GMC) with time was analyzed.
In total, 7436 eligible subjects in kindergarten (3435) and primary school (4001) were included in 2015. The overall GMC (201.7 U/ml) and seropositivity (75.4%) to mumps antibodies in 2016 were significantly lower compared to those in 2015 (218.7 U/ml, 78.4%). Asymptomatic infection occurred within one year in 8.8% of children who received one-dose MMR.
Children who received one-dose MMR in kindergarten and primary school were at high risk of mumps infection, and waning immunity occurred with time. Determining the optimal age for the second dose of MMR in children should be prioritized to prevent mumps epidemics.
在中国,18-24 月龄儿童接种一剂麻疹-腮腺炎-风疹联合疫苗(MMR)。然而,流行性腮腺炎发病率仍居高不下,关于 MMR 接种后腮腺炎免疫持久性的数据有限。本研究旨在描述幼儿园和小学生腮腺炎免疫衰减情况,为确定第二剂次的最佳接种年龄提供科学依据。
2015 年至 2016 年,我们开展了一项关于幼儿园和小学生接种一剂 MMR 的观察性、前瞻性研究。分析时间与腮腺炎血清阳性率和几何平均浓度(GMC)衰减之间的关系。
2015 年共纳入幼儿园(3435 人)和小学(4001 人)7436 名合格受试者。2016 年腮腺炎抗体的总 GMC(201.7 U/ml)和血清阳性率(75.4%)明显低于 2015 年(218.7 U/ml,78.4%)。接种一剂 MMR 后一年内,8.8%的儿童发生无症状感染。
幼儿园和小学生接种一剂 MMR 后,发生腮腺炎感染的风险较高,且随着时间的推移,免疫逐渐衰减。确定儿童 MMR 第二剂次的最佳接种年龄应作为预防流行性腮腺炎的优先事项。